Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with GOVXW
Registration statements such as the Form S-1 and its amendments describe offerings of common units and pre-funded units, each including shares of common stock or pre-funded warrants and common warrants. These documents outline offering sizes, exercise prices, expiration terms, and use of proceeds. Current reports on Form 8-K detail material events, including pricing of public offerings, entry into placement agency and purchase agreements, and Nasdaq listing notifications related to minimum bid price requirements.
Through this filings page, users can review quarterly and annual reports, registration statements, and 8-Ks to understand how GeoVax finances its clinical-stage vaccine and immunotherapy programs, including the role of warrants like those trading as GOVXW. AI-powered tools on the platform can help summarize lengthy prospectuses and 8-K disclosures, highlight key terms of warrant offerings, and surface notable risk factor and capital structure changes. Investors can also use the filings feed to monitor subsequent equity raises, changes in warrant terms, and updates tied to government contracts or clinical milestones that may influence the value of the underlying common stock and related warrants.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,675,610 shares of GeoVax Labs common stock, representing 9.54% of the class. Armistice Capital is the investment manager of the direct holder (the Master Fund) and reports shared voting and dispositive power over these shares. The Master Fund disclaims beneficial ownership to the extent it lacks voting or dispositive power under its agreement with Armistice Capital.
The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Steven Boyd, as managing member of Armistice Capital, is reported as having the same shared voting and dispositive power.
GeoVax Labs, Inc. reporting person Kelly T. McKee Jr., listed as Chief Medical Officer, reported a purchase of 1,107 shares of common stock on 08/07/2025 at $0.67 per share. The Form 4 shows transaction code P and reports 3,494 shares beneficially owned following the transaction; no derivative securities are listed.
The Amendment No. 1 to Form S-1 filed by GeoVax Labs, Inc. (symbol: GOVXW) registers a best-efforts public offering of up to 8,333,334 Common Units at an assumed price of $0.90 per unit. Each Common Unit contains one share of common stock and two five-year Common Warrants.
For investors preferring to avoid exceeding 4.99% (or optionally 9.99%) ownership thresholds, the filing also offers up to 8,333,334 Pre-Funded Units, each comprised of one Pre-Funded Warrant plus two Common Warrants. In total, the statement covers up to 25,000,002 shares of common stock issuable upon warrant exercise.
The company is a non-accelerated filer and qualifies as a smaller reporting company. No underwriter is obligated to purchase the securities; sales will commence “as soon as practicable” after effectiveness. The document is preliminary and subject to completion.